AGILeBiotics receives a pre-seed investment from three local investors, i.e. RUG Houdstermaatschappij BV Stichting Ir G.J. Smid Fonds BV Hanzepoort BV With this financial support, AGILeBiotics has launched its drug discovery and development program, and envisions advancing first antibiotic candidates into late pre-clinical development in 2018.
Menu
